Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

scPharmaceuticals Announced Topline Results From The Pharmacokinetic Study Of SCP-111, An Investigational, Low Volume, Ph-neutral Formulation Of Furosemide Administered Via An Autoinjector As An Alternative To The Current On-body Infusor Used With Furoscix

Author: Benzinga Newsdesk | August 12, 2024 06:04am

Key highlights of the topline results from the study:

SCP-111 demonstrated a bioavailability of 107.3% (90% CI: 103.9 - 110.8), achieving the 90% confidence interval limit of 80 to 125 percent
Participants that received SCP-111 had similar urine output, urinary sodium excretion and urinary potassium excretion at 6, 8 and 12 hours compared to IV furosemide
Participants reported a median pain score of 0 across all time points assessed
The most common adverse events with SCP-111 were localized to the injection site and systemic adverse events were consistent with those reported in the prescribing information for intravenous and oral furosemide

Posted In: SCPH